Literature DB >> 32554552

How Tumor Cell Dedifferentiation Drives Immune Evasion and Resistance to Immunotherapy.

Jinyang Li1,2,3, Ben Z Stanger4,2,3.   

Abstract

Immunotherapy has revolutionized cancer treatment, yet most patients do not respond. While tumor antigens are needed for effective immunotherapy, a favorable tumor immune microenvironment is also critical. In this review, we discuss emerging evidence that tumor cells exploit cellular plasticity and dedifferentiation programs to avoid immune surveillance, which in turn drives metastatic dissemination and resistance to immunotherapy. A deeper understanding of these programs may provide novel opportunities to enhance the efficacy of existing immunotherapies. ©2020 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32554552      PMCID： PMC7541560          DOI： 10.1158/0008-5472.CAN-20-1420

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


  73 in total

1.  A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing.

Authors:  Deng Pan; Aya Kobayashi; Peng Jiang; Lucas Ferrari de Andrade; Rong En Tay; Adrienne M Luoma; Daphne Tsoucas; Xintao Qiu; Klothilda Lim; Prakash Rao; Henry W Long; Guo-Cheng Yuan; John Doench; Myles Brown; X Shirley Liu; Kai W Wucherpfennig
Journal:  Science       Date:  2018-01-04       Impact factor: 47.728

Review 2.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Authors:  Padmanee Sharma; Siwen Hu-Lieskovan; Jennifer A Wargo; Antoni Ribas
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

3.  Quiescent Tissue Stem Cells Evade Immune Surveillance.

Authors:  Judith Agudo; Eun Sook Park; Samuel A Rose; Eziwoma Alibo; Robert Sweeney; Maxime Dhainaut; Koichi S Kobayashi; Ravi Sachidanandam; Alessia Baccarini; Miriam Merad; Brian D Brown
Journal:  Immunity       Date:  2018-02-20       Impact factor: 31.745

4.  A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.

Authors:  Milena P Mak; Pan Tong; Lixia Diao; Robert J Cardnell; Don L Gibbons; William N William; Ferdinandos Skoulidis; Edwin R Parra; Jaime Rodriguez-Canales; Ignacio I Wistuba; John V Heymach; John N Weinstein; Kevin R Coombes; Jing Wang; Lauren Averett Byers
Journal:  Clin Cancer Res       Date:  2015-09-29       Impact factor: 12.531

5.  MYC regulates the antitumor immune response through CD47 and PD-L1.

Authors:  Stephanie C Casey; Ling Tong; Yulin Li; Rachel Do; Susanne Walz; Kelly N Fitzgerald; Arvin M Gouw; Virginie Baylot; Ines Gütgemann; Martin Eilers; Dean W Felsher
Journal:  Science       Date:  2016-03-10       Impact factor: 47.728

Review 6.  Cancer-testis antigens: Unique cancer stem cell biomarkers and targets for cancer therapy.

Authors:  Olga Gordeeva
Journal:  Semin Cancer Biol       Date:  2018-08-29       Impact factor: 15.707

7.  Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia.

Authors:  Yuliya Pylayeva-Gupta; Kyoung Eun Lee; Cristina H Hajdu; George Miller; Dafna Bar-Sagi
Journal:  Cancer Cell       Date:  2012-06-12       Impact factor: 31.743

8.  Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases.

Authors:  Arnaud Pommier; Naishitha Anaparthy; Nicoletta Memos; Z Larkin Kelley; Alizée Gouronnec; Ran Yan; Cédric Auffray; Jean Albrengues; Mikala Egeblad; Christine A Iacobuzio-Donahue; Scott K Lyons; Douglas T Fearon
Journal:  Science       Date:  2018-05-17       Impact factor: 47.728

Review 9.  Emerging Contributions of Cancer/Testis Antigens to Neoplastic Behaviors.

Authors:  Zane A Gibbs; Angelique W Whitehurst
Journal:  Trends Cancer       Date:  2018-09-20

Review 10.  Dedifferentiation and reprogramming: origins of cancer stem cells.

Authors:  Dinorah Friedmann-Morvinski; Inder M Verma
Journal:  EMBO Rep       Date:  2014-02-14       Impact factor: 8.807
View more
  8 in total

1.  Mapping Phenotypic Plasticity upon the Cancer Cell State Landscape Using Manifold Learning.

Authors:  John G Lock; Smita Krishnaswamy; Christine L Chaffer; Daniel B Burkhardt; Beatriz P San Juan
Journal:  Cancer Discov       Date:  2022-08-05       Impact factor: 38.272

2.  Simultaneous and Spatially-Resolved Analysis of T-Lymphocytes, Macrophages and PD-L1 Immune Checkpoint in Rare Cancers.

Authors:  Karina Cereceda; Nicolas Bravo; Roddy Jorquera; Roxana González-Stegmaier; Franz Villarroel-Espíndola
Journal:  Cancers (Basel)       Date:  2022-06-06       Impact factor: 6.575

Review 3.  Perspectives for 3D-Bioprinting in Modeling of Tumor Immune Evasion.

Authors:  Rafał Staros; Agata Michalak; Kinga Rusinek; Krzysztof Mucha; Zygmunt Pojda; Radosław Zagożdżon
Journal:  Cancers (Basel)       Date:  2022-06-26       Impact factor: 6.575

Review 4.  Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC.

Authors:  Fenglong Bie; He Tian; Nan Sun; Ruochuan Zang; Moyan Zhang; Peng Song; Lei Liu; Yue Peng; Guangyu Bai; Bolun Zhou; Shugeng Gao
Journal:  Front Oncol       Date:  2022-02-09       Impact factor: 6.244

Review 5.  Targeting macrophages in hematological malignancies: recent advances and future directions.

Authors:  Wei Li; Fang Wang; Rongqun Guo; Zhilei Bian; Yongping Song
Journal:  J Hematol Oncol       Date:  2022-08-17       Impact factor: 23.168

6.  A high-throughput drug screen reveals means to differentiate triple-negative breast cancer.

Authors:  Milica Vulin; Charly Jehanno; Atul Sethi; Ana Luísa Correia; Milan M S Obradović; Joana Pinto Couto; Marie-May Coissieux; Maren Diepenbruck; Bogdan-Tiberius Preca; Katrin Volkmann; Priska Auf der Maur; Alexander Schmidt; Simone Münst; Loïc Sauteur; Michal Kloc; Marta Palafox; Adrian Britschgi; Vincent Unterreiner; Olaf Galuba; Isabelle Claerr; Sandra Lopez-Romero; Giorgio G Galli; Daniel Baeschlin; Ryoko Okamoto; Savas D Soysal; Robert Mechera; Walter P Weber; Thomas Radimerski; Mohamed Bentires-Alj
Journal:  Oncogene       Date:  2022-08-25       Impact factor: 8.756

Review 7.  Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance.

Authors:  Xiaoting Zhou; Yanghong Ni; Xiao Liang; Yi Lin; Biao An; Xiang He; Xia Zhao
Journal:  Front Immunol       Date:  2022-09-15       Impact factor: 8.786

8.  LSD1 inhibition induces differentiation and cell death in Merkel cell carcinoma.

Authors:  Lukas Leiendecker; Pauline S Jung; Izabela Krecioch; Tobias Neumann; Alexander Schleiffer; Karl Mechtler; Thomas Wiesner; Anna C Obenauf
Journal:  EMBO Mol Med       Date:  2020-10-07       Impact factor: 12.137
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.